title: Long-acting injectable bromocriptine (Parlodel LAR) in the chronic treatment of prolactin-secreting macroadenomas.
abstract: OBJECTIVE
  To evaluate the efficacy and tolerability of Parlodel LAR (Sandoz, Basel, Switzerland), a long-acting injectable bromocriptine, in PRL-secreting macroadenomas.
  
  
  METHODS
  Eleven patients with macroprolactinomas were studied in an academic environment in an open and prospective protocol. Ten patients were followed for 6 months and 8 for 1 year. Fifty to 200 mg IM of Parlodel LAR were administered every 28 days.
  
  
  RESULTS
  At the end of the 1st month, 64% of the patients had PRL suppression of > 75% of baseline values. After 1 year, 88% of the cases had PRL suppression of > 90%. Persistent PRL normalization was seen in three cases. Tumor shrinkage was seen in 64% of the patients on day 5, in 73% on day 28, and in 90% after 6 months of treatment. Early visual field improvement was seen in 83% of the cases. All patients had improvement of clinical symptoms.
  
  
  CONCLUSIONS
  Parlodel LAR is well tolerated and very effective in the long-term treatment of patients with PRL-secreting macroadenomas.
authors: Escola Paulista de Medicina, São Paulo, Brazil.
authors: A M
authors: AM
authors: Lengyel
authors: W
authors: W
authors: Mussio
authors: P
authors: P
authors: Imamura
authors: J G
authors: JG
authors: Vieira
authors: I
authors: I
authors: Lancranjan
mesh_terms: D000236:Adenoma / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D001971:Bromocriptine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D011388:Prolactin / Q000097:blood / Q000378:metabolism*; D015175:Prolactinoma / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D011446:Prospective Studies; D014794:Visual Fields
chemical_list: D003692:Delayed-Action Preparations; D001971:Bromocriptine; D011388:Prolactin